THE USE OF BIOACTIVE STENT HELIFLEX

ON PATIENTS WITH ATHEROSCLEROTIC

LESIONS OF SUPERFICIAL FEMORAL

ARTERY: THE BEGINNING OF THE STUDY

A.OLESCHUK , M. GENERALOV, D. MAYSTRENKO, A. IVANOV, A.KHMELNITSKIY

FSBI «RUSSIAN RESEARCH CENTER OF RADIOLOGY AND SURDICAL TEHNOLOGIES» OF

MINISTRY OF HELTHCARE OF THE RUSSIAN FEDERATION, DEPARTMENT OF VASCULAR

SURGERY

St. Petersburg, Russia

2017

Disclosure

I do not have any potential conflict of interest

OBJECTIVE

To evaluate the results of the use of stents with

bioactive coating based in the treatment of

patients with atherosclerotic lesions of the

superficial femoral artery (SFA)

MATERIAL AND METHODS

Between January 2014 to December 2015

25 patient : 16 men and 9 women

Average age 61,3 ± 9,2 years

Classifying TASC II :

Type A - 9 (36 %)

Type B – 7 (28 %)

Type C – 9 (36 %)

MATERIAL AND METHODSclinical characteristics of the patients

MATERIAL AND METHODS Characteristics of the arterial bed of the lower limbs *

*according to CT and/or x-ray contrast angiography

MATERIAL AND METHODS Characteristics of the arterial bed of the lower limbs *

*according to CT and/or x-ray contrast angiography

MATERIAL AND METHODS

To determine the levels of blood nitric oxide used immunosorbent method

Assessment of the patency of the design was carried out according to the

ultrasonic duplex scanning is carried out in terms 30 days, 6 and 12 months

BIOACTIVE STENT HELIFLEX

(HexacatH, France)

Clinical outcome of registries and trials employing bioactive stents in coronary artery

EVIDENCE Registry

Mosseri et al

Pori Registry

TIBET Registry

TITAX AMI Trial

Bio Active Stent demonstrating reduced neointimal

proliferation

Bare Metal Stent (Control) showing neointimal proliferation.

BASE-ACS trial

BIOACTIVE STENT HELIFLEX

(HexacatH, France)

Stents diameter 6 to 8 mm

A length from 50 to 200 mm

ANGIOGRAHPY OF A PATIENT WITH DAMAGE

SFA

No-marker of endotelium disfunctionN=24mmol\l

RESULTS

Procedure success rate was 100 %

Levels of NO : preoperative average was 18,9 ± 2,3 mmol/l, after the

operation 28,9 ± 4,1 mmol/l

RESULTS

CONCLUSION

The use of stents with a bioactive coating based on titanium

oxynitride increases the level of NO in blood that can help to

prolong the period of function of endovascular construction.

The first data on the primary patency of stents of this type are

expected to improve long-term results of treatment of patient

with atherosclerotic lesions of the SFA.

THANK YOU!

THE USE OF BIOACTIVE STENT HELIFLEX

ON PATIENTS WITH ATHEROSCLEROTIC

LESIONS OF SUPERFICIAL FEMORAL

ARTERY: THE BEGINNING OF THE STUDY

A.OLESCHUK , M. GENERALOV, D. MAYSTRENKO, A. IVANOV, A.KHMELNITSKIY

FSBI «RUSSIAN RESEARCH CENTER OF RADIOLOGY AND SURDICAL TEHNOLOGIES» OF

MINISTRY OF HELTHCARE OF THE RUSSIAN FEDERATION, DEPARTMENT OF VASCULAR

SURGERY

St. Petersburg, Russia

2017